Amneal Pharmaceuticals Hits New 52-Week High at $17.76

Amneal Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 17.76 on June 25, 2026. This achievement marks a remarkable increase in the stock's performance, with a one-year gain of 152.85%, significantly outpacing the S&P 500's performance of 20.77% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology industry, Amneal Pharmaceuticals has a market capitalization of USD 3,728 million. The stock's price-to-earnings (P/E) ratio stands at 22.00, reflecting its valuation relative to earnings. Notably, the company has a debt-to-equity ratio of -32.15, indicating a unique financial structure. Despite the absence of a dividend yield, the stock's performance metrics highlight its dynamic position in the market. The previous 52-week low was recorded at USD 7.67, underscoring the significant upward movement in the stock price. This new high reflects the company's ongoing developments and market activities within the competitive landscape of the pharmaceuticals sector.